# Pizarra — PT-pseudo_d217629c323a (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d217629c323a
Task: 1

Encounter: Urology - outpatient on 08 Jan 2025.
Referrer: Dr. S. de Vries (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 3.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.126 ng/mL²
  - PSA velocity: 1.39 ng/mL/yr
  - Prior PSA: 2.6 ng/mL
  - Prostate volume: 30.21 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.79094493 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 3.8 ng/mL. PI-RADS 4. PSAD 0.13. Prostate volume 30 mL. DRE nodus. csPCa 0.79.

Vitals: weight 83 kg, height 183 cm, BMI 24.8, BP 102/63 mmHg, HR 88 bpm. Smoking: Non-smoker.

Chief complaint: Routine monitoring for a previously identified Gleason 3+4 lesion alongside a recent PSA increase to 3.8 ng/mL.

History: A seventy-year-old retired postal worker, married and living with his partner, attends for ongoing surveillance of a previously diagnosed Gleason 3+4 focus. Current laboratory data shows a PSA elevation to 3.8 ng/mL. This gentleman is a non-smoker, maintains a robust routine that includes biweekly tennis matches, and limits alcohol intake to roughly six standard drinks weekly. Lower urinary tract complaints are negligible, reflected by an IPSS score of 2, with explicit denial of haematuria or erectile difficulties. Ophthalmic history includes bilateral cataract removal three years back, necessitating large-print materials for mild visual deficits, alongside a recent dental screening. Systemic review reveals no unexplained weight reduction, skeletal discomfort, or constitutional complaints. Concurrently, no comorbid conditions or active pharmacological agents are recorded.

Physical examination: DRE reveals a gland measuring approximately 30 mL, characterized by a firm, discrete nodule within the right lobe. The remaining prostatic tissue exhibits symmetry without tenderness, and palpation of the inguinal regions detects no lymphadenopathy. Vital parameters remain stable, with general survey showing no evidence of systemic pathology.

Patient info: retired postal worker; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 6 units / week; exercise Tennis 2x/week; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.51 +/- 0.20   (95% CI 0.14-0.88)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 5.9 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=3.8, age=70.0, psad=0.126, dre_ord=1.0, vol=30.21, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PI-RADS=4, PSA=3.8, prior biopsy Positive, csPCa probability=0.79) and could not weigh the clinical context, such as the patient's low PSA density (0.126 ng/mL²), the specific nature of the prior positive biopsy, or the clinical context of the Gleason 3+4 diagnosis.

WHY THE SUGGESTION COULD BE WRONG
The prior suggestion of BIOPSY (p=0.51 +/- 0.20) is highly uncertain, as the guideline criterion explicitly states the panel is undetermined. The statistical prior could be wrong because it failed to account for the prior positive biopsy status, which should fundamentally change the question from "does he have cancer" to "is the existing lesion stable or progressed," which the prior did not model. Furthermore, the wide error bar suggests the classifier cannot distinguish between the two options based on the limited input.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
laboratory panel - to confirm PSA density and check for other relevant lab markers.
previous GP / urology notes - to ascertain the specific findings of the prior positive biopsy and the context of the Gleason 3+4 diagnosis.
previous notes - to determine if a repeat biopsy is indicated based on the prior positive result.
GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Catharina Ziekenhuis, Eindhoven | 05 Jan 2025 | Multiparametric MRI Prostate
PI-RADS 4 lesion in the right mid-gland. Lesion size: 12 mm. No extraprostatic extension or seminal vesicle invasion observed.
get_psa_trend
PSA trend shows a rising trajectory: 0.6 ng/mL (Sep 2022) -> 1.5 ng/mL (Nov 2023) -> 3.8 ng/mL (Jan 2025).
get_previous_notes
18 Jul 2023: Previous surveillance tracking a climb to 2.6 ng/mL by Nov 2023. Referral for comprehensive evaluation and biopsy deliberation was warranted.
get_lab_results
PSA: 3.8 ng/mL (30 Nov 2024). %Free PSA: 22%.

NOT RETRIEVED
The specific ISUP grade group or Gleason score of the prior positive biopsy was not documented in the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
Findings that argue FOR sampling this patient now:
- Rising PSA velocity: 1.39 ng/mL/yr.
- New/changed lesion on MRI: PI-RADS 4 lesion (12 mm) noted on the recent MRI.
- Prior surveillance context: Previous notes indicate a trajectory leading to a referral for biopsy deliberation.

Findings that argue AGAINST sampling this patient now:
- Prior biopsy status: Prior biopsy was Positive (no grade documented).
- Clinical stability: Patient reports negligible LUTS and no systemic symptoms.

WHERE THIS LEANS
The evidence suggests a need for further characterization due to the rising PSA and the presence of a new PI-RADS 4 lesion, despite the prior positive result. This leans toward recommending a re-biopsy or further characterization as per the guideline criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the prior positive biopsy status is noted, the rising PSA velocity of 1.39 ng/mL/yr and the presence of a new PI-RADS 4 lesion on the MRI warrant further characterization. The evidence suggests a need for re-biopsy to determine if the existing lesion has progressed, which is the key question the retrieved documents address. The conference resolved the conflict between the statistical prior and the guideline criterion by finding that the retrieved evidence supports proceeding with further sampling.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
